Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

Benzinga · 2d ago
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.